Literature DB >> 6201934

Bleomycin--mode of action with particular reference to the cell cycle.

P R Twentyman.   

Abstract

Over the last four years, investigations into the mechanism of interaction between bleomycin and DNA have been pursued at a rapid pace. This is, no doubt, because of the potential of bleomycin as a tool for molecular biology. It seems likely that the precise nature of the interaction between Fe(II), oxygen and bleomycin will be elucidated in the near future together with the nature of the binding between the complex and DNA. More information on the mechanism of strand scission including the involvement of free radical mechanisms and sequence specificity may also be expected. In contrast to this picture of rapid progress at the molecular level, interest in studies of bleomycin action at the cellular level appears to have waned. This is despite the fact that most of the important questions which have been raised regarding effects of the drug on cell cycle progression, the possibility of a selective action on on-cycling cells and the nature of 'recovery from potentially-lethal damage' remain unresolved. There is no doubt that, for most cell types, bleomycin produces a block at the early G2 stage of the cell cycle. There is considerable doubt, however, as to how many of the cells blocked for a significant period remain clonogenically viable. This question is amenable to being answered using a vital DNA stain, such as Hoechst 33342, and cell sorting but this does not appear to have been done. The relationship between G2 blockage and repair of DNA damage has also not been resolved. Neither has the question of whether or not DNA breaks which remain unrepaired are different in nature from the majority of repairable lesions. The data on the relative sensitivity of exponential and plateau phase cells are conflicting and their in vivo significance unclear. Well designed experiments to examine the bleomycin sensitivity of those cells in solid tumors which survive radiation treatment could help to answer this question. Evidence that the phenomenon of 'recovery from potentially lethal damage' is therapeutically-exploitable is mainly lacking. It would be of great relevance to known whether or not the effect can be observed in normal tissues. However, the evidence that the effect is not simply an artefact of clonogenic assay procedures is scanty and this possibility must be borne in mind.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6201934     DOI: 10.1016/0163-7258(83)90022-0

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  12 in total

1.  A DNA2 Homolog Is Required for DNA Damage Repair, Cell Cycle Regulation, and Meristem Maintenance in Plants.

Authors:  Ning Jia; Xiaomin Liu; Hongbo Gao
Journal:  Plant Physiol       Date:  2016-03-07       Impact factor: 8.340

2.  Comparison of cancer chemotherapeutic agents in asynchronous and synchronous 9L cells.

Authors:  S D Henderson; B F Kimler; M L Barnes
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

3.  Quantitative measurement of single- and double-strand breakage of DNA in Escherichia coli by the antitumor antibiotics bleomycin and talisomycin.

Authors:  C K Mirabelli; C H Huang; R G Fenwick; S T Crooke
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

4.  Growth phase dependency of chromatin cleavage and degradation by bleomycin.

Authors:  C W Moore; C S Jones; L A Wall
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

5.  Postconfluency MDCK monolayers as an in vitro model of solid tumor chemosensitivity.

Authors:  P Skehan; J Thomas; S J Friedman
Journal:  Cell Biol Toxicol       Date:  1986-09       Impact factor: 6.691

Review 6.  Hypoxia and drug resistance.

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

Review 7.  Cancer cell interactions with injured or activated endothelium.

Authors:  R Lafrenie; S G Shaughnessy; F W Orr
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

8.  Biological and biochemical activities of the novel antitumor antibiotic PD 114,759 and related derivatives.

Authors:  D W Fry; J L Shillis; W R Leopold
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

9.  Effect of Fluosol-DA/O2 on the antitumor activity and pulmonary toxicity of bleomycin.

Authors:  B A Teicher; J S Lazo; W W Merrill; A E Filderman; C M Rose
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  Platinum-dye complexes inhibit repair of potentially lethal damage following bleomycin treatment.

Authors:  Y Wang; T S Herman; B A Teicher
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.